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Functional human hepatocytes xenografted into the liver of mice can be used as a model system to study pharmacokinetics, in-
fection of hepatitis viruses, and the efficacy of hepatitis vaccines. Significant levels of liver xeno-repopulation have been re-
ported in Fah−/−Rag2−/−Il2rg−/− mice. However, the high mortality and low breeding rate of this model may hinder its applica-
tion. A new model, termed Fah−/−Nod/Scid mice, which combines the advantages of liver repopulation in Fah−/− mice with the 
ease of xenotransplantation in Nod/Scid mice was obtained by gradual cross-breeding. Fah−/−Nod/Scid mice were easily main-
tained in breeding colonies and in adult animal care facilities. FK506 treatment combined with gradual withdrawal of NTBC 
before cell transplantation ensured that Fah−/−Nod/Scid mice were susceptible to liver xeno-repopulation by human hepatocytes; 
the proportion of engrafted human hepatocytes reached 33.6%. The function of the expanded human hepatocytes within the 
chimeric liver was confirmed by weight curve analysis, the expression of characteristic proteins, and the biochemical analysis 
of liver function. These results show that Fah−/−Nod/Scid mice are an ideal humanized liver mouse model with many useful 
applications. 
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Functional human hepatocytes xenografted into the liver of 
mice can be used as a model system to study pharmacoki-
netics, infection by hepatitis viruses, and the efficacy of 
hepatitis vaccines [1–9]. Fumarylacetoacetate hydrolase 
gene knockout mice (Fah−/− mice) have been established as a 
model for hereditary tyrosinemia type I (HT1) disease [10]. 
As one of the most recognized models for liver damage, 
Fah−/− mice have been widely used to study liver repopula-
tion by several types of cells [11,12]. For example, 100 
adult mouse hepatocytes were able to reconstruct 5% of the 
cells within a whole liver (about 2×105 cells) and rebuild the 
structure and function of the hepatic lobules after cell trans-
plantation and proliferation [11–13]. Studies show that 
Fah−/−Rag2−/−Il2rg−/− mice lacking B, T and NK cells are 
susceptible to liver xeno-repopulation by human hepato-
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cytes [7–9]. However, there are some disadvantages to the 
Fah−/−Rag2−/−Il2rg−/− mouse model, including high mortal-
ity rates during breeding, throughout life and after cell 
transplantation, which have presented a barrier to its larger 
scale application [9]. Previously, we successfully treated 
Fah−/−Rag2−/− mice with the immunosuppressants, anti-asialo 
GM1 and FK506 to enable significant levels of liver 
xeno-repopulation by human hepatocytes and human fetal 
liver cells [9]. When infected with sera containing the hepa-
titis B virus (HBV), Fah−/−Rag2−/− mice that have under-
gone liver xeno-repopulation by human hepatocytes develop 
significant levels of HBV DNA and HBV protein. This re-
duces the mortality during breeding and surgery. On the 
basis of the above work, and taking into account the fact that 
the anti-asialo GM1 antibody needed to inhibit NK cell func-
tion is expensive (and needs to be injected every 7 d), we 
committed to the further optimization of the humanized liver 
mouse model. Non-obese diabetic-SCID mice (Nod/Scid) 
have many advantages, such as T and B lymphocyte com-
bined immune deficiency, low NK cell activity, a lack of 
circulating complement and macrophages, and antigen pre-
senting cell dysfunction. They also breed normally [14]. 
Therefore, as Nod/Scid mice have both innate and acquired 
immune deficiency, are less prone to immune escape, and 
have higher rates of xeno-transplantation than Scid mice, 
they were considered to be the best model for xeno-trans-    
plantation.  
Combining the advantages of high levels of liver re-
population seen in Fah−/− mice with the ease of xeno-    
transplantation in Nod/Scid mice, we produced Fah−/−Nod/ 
Scid mice by a process of gradual cross-breeding. Fah−/−Nod/ 
Scid mice were easily maintained in breeding colonies and 
in adult animal care facilities and, as such, could provide a 
large number of homozygous mice for humanized mouse 
liver studies. FK506 treatment combined with gradual 
withdrawal of NTBC before cell transplantation enabled 
Fah−/−Nod/Scid mice susceptible to liver xeno-repopulation 
by human hepatocytes (by up to 30%). The cellular function 
of the expanded human hepatocytes within the chimeric 
liver was confirmed by analysis of weight curves, the ex-
pression of characteristic proteins, and by biochemical 
analysis of liver function. The results show, for the first 
time, that Fah−/−Nod/Scid mice are an ideal humanized liver 
model with many potential applications.  
1  Materials and methods 
1.1  Establishment of Fah−/−Nod/Scid mice 
Nod/Scid, Fah−/− (25–30 g, 129S4 strain) and 129S4 
wild-type mice were raised in an individual ventilated cage 
system in the specific pathogen free grade animal room in the 
animal center of the Second Military Medical University. 
Conditions were circadian rhythm (7:00–19:00), free food 
and acidic water (pH 3.0). Fah−/− mice were given drinking 
water containing NTBC (7.5 μg mL−1).  
Fah−/− mice were crossed with Nod/Scid mice to establish 
the Fah−/−Nod/Scid mouse strain. PCR-based genotyping for 
Fah and Scid was used to determine the genotypes of the 
offspring. The method for Fah genotyping has been de-
scribed previously [10]. Scid genotyping was done as fol-
lows: primers (5′-GGAAAAGAATTGGTATCCAC-3′, 5′-    
AGTTATAACAGCTGGGTTGGC-3′). PCR conditions: 94°C 
for 30 s, 53°C for 30 s, 72°C for 30 s. The PCR products 
were digested overnight with Alu I, separated by electro- 
phoresis on 20% polyacrylamide gels, dyed with 0.5 g mL−1 
ethidium bromide solution and photographed. Digested 
wild-type products were 68 and 11 bp (the 11 bp band is not 
visible in the photograph), and the mutant products were 38, 
28 and 11 bp (the 11 bp band is also not visible). 
1.2  Analysis of immune cells 
Four mice from each strain (Fah−/−, Fah−/−Nod/Scid and 
Fah−/−Rag2−/−Il2rg−/−) were sacrificed under anesthesia. 
Bone marrow cells from the femurs were collected and the 
concentration adjusted to 1×106 cells/tube. After conven-
tional treatment, the cells were incubated with anti-CD3, 
anti-CD19 and anti-NK1.1 primary antibodies (eBioscience) 
and expression detected by flow cytometry using the appro-
priate secondary antibodies (FITC-conjugated anti-mice 
CD3 mAb, FITC-conjugated anti-mice CD19 mAb, or 
PE-conjugated anti-NK1.1; eBioscience). Data from the 
Fah−/− mice were normalized to one. 
1.3  Isolation of human hepatocytes  
Human liver tissue was provided by Eastern Hepatobiliary 
Surgery Hospital, Second Military Medical University 
(Shanghai, China) from donor livers that had been reduced 
in size for allotransplantation. Clinical test results confirmed 
that markers for HBV, HCV, HIV and Treponema pallidum 
were all negative. Biopsy confirmed that these were normal 
liver tissues. The method used to separate human hepato-
cytes has been described previously [12]. Cell viability was 
determined by trypan blue staining. 
1.4  Cell transplantation and FK506 treatment  
Twenty Fah−/−Nod/Scid mice (six mice in the control group) 
were used for cell transplantation. Seven days before trans-
plantation, the level of NTBC in the drinking water was 
reduced to 50% for 3 d, and further reduced to 25% for 3 d. 
NTBC was discontinued 2 d before transplantation. This 
treatment induced liver injury ahead of schedule, and pro-
moted the engraftment and proliferation of the transplanted 
cells. 
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FK506 (Astellas Ireland Co.; 7.5 μg mL−1) was dissolved 
in the drinking water and administered to adult mice to 
achieve a dose of 1 μg g−1 body weight per day.  
1.5  Molecular biology 
For the molecular assays, the human Alu sequence within 
the chimeric liver was amplified by PCR as described pre-
viously [2]. To further determine whether the expanded 
human hepatocytes had normal cell function, Western blot-
ting was performed to detect the expression of the Fah pro-
tein in the chimeric liver. The livers of 129S4 wild-type 
mice, Fah−/− mice and chimeric mice were collected and the 
liver proteins extracted and quantified. Total protein (50 μg) 
was separated on acrylamide gels, and transferred onto a 
nitrocellulose membrane. Blots were blocked with blotto 
(5% nonfat milk powder in PBS plus 0.1% Tween 20) for 1 
h at room temperature. Fah primary antibody (1:3000; Af-
finitein) was added for 1 h at room temperature. Blots were 
washed three times with PBS/0.1% Tween 20 before incu-
bation with the secondary antibody (HRP conjugated goat 
anti-rabbit IgG, 1:10000; Sigma) for 1 h. Blots were then 
washed briefly and proteins detected using an ECL kit (Ab-
cam). 
1.6  Hematoxylin & eosin (H & E) staining and immu-
nohistochemical analysis 
Transplanted mice underwent partial hepatectomy either 3 d 
or six weeks after cell transplantation, and were sacrificed 
after 12 weeks. Sections (4 μm thick) were examined by 
immunohistochemistry with antibodies to Fah, Alb, AAT, 
and by H & E staining. Briefly, liver samples were fixed in 
4% paraformaldehyde and embedded in paraffin. Sections 
were dewaxed with xylene, rehydrated, incubated with pri-
mary antibodies (Fah, Affinitein, 1:3000; hAlb, Bethyl, 
1:200; Alb, DAKO, 1:200; or hAAT, Therm, 1:1000) and 
then incubated with HRP-conjugated goat anti-rabbit IgG 
secondary antibodies, followed by detection with DAB 
(DAKO) and counterstaining with Mayer’s hematoxylin 
solution (Sigma). For immunofluorescence, a fluorescence 
labeled secondary antibody (Donkey α Goat, 1:800 or 
Donkey α Rabbit, 1:800; Jackson) was added before mount-
ing with DAPI mounting medium (Dapi-Fluoromount-G; 
SouthernBiotech). Sections were then observed under a 
fluorescence microscope.  
1.7  Weight curve and biochemical analysis of liver 
metabolic function  
Body weights before treatment were normalized to one, and 
a weight curve drawn 1–8 weeks after transplantation of 
human hepatocytes. Serum was collected from the retro or-
bital vein of anesthetized mice. Biochemical analysis of liver 
metabolic function was done as previously described [15]. 
Human albumin (hAlb) ELISA kits (Bethyl) were used to 
measure hAlb protein levels in accordance with the manu-
facturer’s instructions. 
1.8  Statistical analysis 
The level of liver repopulation was evaluated using Adobe 
Photoshop CS3 software. Data were expressed as mean±SD. 
Comparison of data was done using the Student’s t-test and 
statistical software (SPSS 10.0; SPSS Inc.). A P-value of 
<0.05 was considered statistically significant. 
2  Results 
2.1  Establishment of Fah−/−Nod/Scid mice and analysis 
of immune cells 
The results of the genotyping analysis of Fah−/−Nod/Scid 
mice are shown in Figure 1A and B. Fah+/− mice had both 
the wild-type band (~180 bp) and the mutant band (~240 
bp), while Fah−/− mice only had the mutant band (Figure 
1A). The PCR products from the Nod/Scid gene were di-
gested and electrophoresed through vertical strips. The 
wild-type product was 68 bp and the mutant products were 
38 and 28 bp (Figure 1B).  
Flow cytometry was used to detect the number of T cells 
(CD3+), B cells (CD19+) and NK cells (CD3−NK1.1+) in the 
Fah−/−, Fah−/−Nod/Scid, and Fah−/−Rag2−/−Il2rg−/− mice. Com-
pared with the Fah−/− mice, Fah−/−Nod/Scid mice lacked T 
cells, B cells and NK cells, signifying complete immune 
deficiency. The extent of immunodeficiency in Fah−/−Nod/ 
Scid mice was equal to that in the Fah−/−Rag2−/−Il2rg−/− mice 
(Figure 1C). 
2.2  Liver xeno-repopulation in Fah−/−Nod/Scid mice 
Human hepatocytes (1×106) were injected into the spleens 
of 14 Fah−/−Nod/Scid mice. Six Fah−/−Nod/Scid mice were 
injected normal saline as the control group. Gradual with-
drawal of NTBC one week before transplantation caused 
liver injury in Fah−/−Nod/Scid mice and induced the en-
graftment of transplanted human hepatocytes. At the same 
time, mice were given FK506 to promote the proliferation 
of human hepatocytes. The Fah enzyme was detected in 
transplanted cells using immunohistochemistry to determine 
the level of liver repopulation in the Fah−/− mice.  
No Fah-positive hepatocytes were found in the Fah−/−Nod/ 
Scid control group (Figure 2A). A few engrafted human 
hepatocytes were seen in the recipients in the experimental 
groups 3 d after transplantation. Fah-positive hepatocytes 
were observed as individual cells or nodules containing 2–4 
cells (Figure 2B). A Fah immunoassay conducted six weeks 
after transplantation showed up to 8.2% engrafted Fah-         
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Figure 1  Establishment of Fah−/−Nod/Scid mice strain and analysis of immune cells. A, Fah genotyping analysis. B, Nod/Scid genotyping analysis. C, 
Analysis of immune cells: Fah−/−Nod/Scid mice lacked T cells, B cells and NK cells. Fah, Fah−/− mice; FRG, Fah−/−Rag2−/−Il2rg−/− mice; FN, Fah−/−Nod/Scid  
mice. 
 
Figure 2  Liver xeno-repopulation in Fah−/−Nod/Scid mice by human 
hepatocytes. A, No Fah-positive hepatocytes were found in the control 
group without cell transplantation. B, A few engrafted human hepatocytes 
were seen in the experimental groups 3 d after transplantation (arrows). C, 
Typical nodules formed by human hepatocytes were seen after six weeks. 
D, Liver xeno-repopulation in Fah-/-Nod/Scid mice by human hepatocytes 
after 12 weeks. E, Comparison of liver repopulation in Fah−/−Nod/Scid  
mice after six and 12 weeks. 
positive hepatocytes (range, 0.6%−18.5%) (Figure 2C and 
E). This increased to 17.4% (range, 5.2%−33.6%) after 12 
weeks (Figure 2D and E). Overall, chimerism was success-
fully induced in 57.1% (8/14) of the mice. 
2.3  Assay of human hepatocytes within chimeric livers 
A PCR assay was used to detect human Alu gene-specific 
DNA sequences. The Alu sequence (440 bp) was amplified 
from the chimeric livers, confirming the presence of human 
hepatocytes (Figure 3A). The Fah protein was confirmed in 
chimeric livers by Western blotting. No Fah protein was 
detected in the livers of Fah−/−Nod/Scid mice that did not 
undergo hepatocyte transplantation. This shows that the Fah 
protein is expressed in engrafted human hepatocytes, which 
proliferated within the chimeric livers of Fah−/−Nod/Scid 
mice (Figure 3B). 
2.4  Human hepatocytes within chimeric livers are 
functional 
Immunohistochemical staining for functional proteins ex-
pressed by human hepatocytes was carried out. A non-spe-     
cific albumin (Alb) antibody (reacts with albumin in hepa-
tocytes from both mice and humans), and human-specific 
(no cross reaction with murine hepatocytes) Alb and α-anti-     
trypsin (AAT) antibodies were used. The results showed that 
human hepatocytes were successfully engrafted, and were 
proliferating and expressing functional proteins in the livers 
of Fah−/−Nod/Scid mice (Figure 4A–C). This was further 
confirmed by serial staining using hAlb and hAAT antibod-
ies (Figure 4D and E). H & E staining indicated that human 
hepatocytes contributed to the formation of the hepatic plate  
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Figure 3  Assay of human hepatocytes in chimeric livers. A, Human Alu gene-specific DNA sequences (440 bp) were only amplified from chimeric livers 
(124#, 155#). B, Fah protein was identified in chimeric livers by Western blotting. Lane 1, Fah−/− mice; Lane 2, 129S4 wt mice; Lanes 3–5, chimeric liver  
mice with human hepatocytes (3, 124#; 4, 155#; 5, 163#). 
 
Figure 4  Albumin and α-antitrypsin are expressed in human hepatocytes. A, Non-specific immunofluorescence staining of albumin in mouse and human 
hepatocytes (green). B, Immunofluorescence staining of human-specific albumin in human hepatocytes (red). C, Merged picture of A and B and DAPI nu-
clear staining. Mice hepatocytes are green and human hepatocytes are yellow in the overlay. D and E, Serial staining of human specific albumin and 
α-antitrypsin in chimeric livers. F, H & E staining showed that the proliferated human hepatocytes participated in the composition of the hepatic plate and  
maintained the integrity of the liver lobules. 
and maintained the integrity of the liver lobules (Figure 4F). 
As Fah contributes to the metabolism of tyrosine, its ex-
pression confirmed that the proliferated human hepatocytes 
had normal metabolic function (Figure 2B–D). 
2.5  Liver function of humanized liver mice 
Fah−/− mice were healthy and reproduced normally while 
treated with NTBC. Once NTBC was withdrawn, Fah−/− 
mice lost weight gradually and died of subacute liver failure 
after 3–6 weeks. The recovery of liver metabolic function in 
Fah−/− mice is reflected by a change in body weight [7,9]. 
Because the liver has a strong compensatory ability, liver 
function in Fah−/− mice returns to normal when the per-
centage of functional human hepatocytes in the chimeric 
liver exceeds 20% [9]. In the present study, we also found 
that chimeric mice with high levels of liver repopulation 
gradually gained weight by four weeks after human hepa-
tocyte transplantation, indicating recovery of liver function 
in these mice (Figure 5A).  
Metabolic parameters were used to analyze the recovery 
of metabolic function in the human hepatocytes. Expression 
of hAlb in the serum of the recipients indicated that the 
synthetic function of the human hepatocytes was intact after 
liver repopulation; serum hAlb levels of up to 3.12 mg mL−1 
were measured (Figure 5B). As summarized in Table 1, 
analysis of recipient serum indicated the recovery of meta-
bolic function after liver xeno-repopulation. These results 
show that human hepatocytes can proliferate in the chimeric 
liver have normal function. 
3  Discussion 
Functional human hepatocytes xenografted into the livers of 
mice can be used as a model system to study pharmacoki-
netics, hepatitis infection and the efficacy of hepatitis vac-
cines [1–9]. There are many studies of humanized mice 
based on uPA transgenic [1–6] and Fah knockout mouse 
models [7–9] and levels of liver xeno-repopulation range 
from 10% to 90%. However, uPA mice have several disad-
vantages [1,2,16,17]: (i) high rates of neonatal death during  
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Figure 5  Weight curve and detection of human serum albumin. A, Weight curve. The weight of No. 155 (chimeric mice) stopped declining, but gradually 
increased four weeks after human hepatocyte transplantation. The weight of No. 106 (Fah−/−Nod/Scid mice on NTBC) increased steadily, while the weight of 
No. 119 (Fah−/−Nod/Scid mice, off NTBC and without human hepatocytes transplantation) declined gradually and the mice died after six weeks. B, Detection  
of serum albumin in chimeric mice secreted by human hepatocytes. 
Table 1  Biochemical analysis of metabolic function after human hepatocyte transplantation 
Mouse ALT (U L−1) AST (U L−1) Total bilirubin (μmol L−1) Fah activity (μmol min−1 g−1) Tyrosine (μmol L−1) 
129S4 wt 18.5±3.3 88.1±19.9 0.5±0.4 72.5±10.2 81.5±28.6 
Fah−/−Nod/Scida) 267.6±78.5 735.5±412.4 62.8±23.7 0.4±0.3 812.4±156.8 
121# 86.7 187.4 18.5 20.8 222.7 
123# 112.5 179.6 26.7 15.6 258.5 
124# 54.6 125.5 3.9 40.2 162.3 
155# 68.2 154.6 4.8 31.5 185.6 
163# 70.8 165.7 10.6 25.3 194.8 
a) Bodyweight fell by over 20% after withdrawal of NTBC. 
 
 
colony breeding; (ii) transplantation of hepatocytes into 
newborn (within the 2nd week of life) is technically diffi-
cult due to a bleeding disorder in these mice; (iii) there is 
uncontrollable selection for donor cells; (iv) there is 
auto-reversion of endogenous hepatocytes; and (v) kidney 
damage is induced by human complement. These deficien-
cies make it difficult to establish a stable and reliable animal 
model. Recently, robust liver xeno-repopulation from hu-
man hepatocytes was seen in Fah−/−Rag2−/−Il2rg−/− mice 
[7–9]. However, maintenance of Fah−/−Rag2−/−Il2rg−/− mice 
during colony breeding, growing and cell transplantation is 
difficult, with high mortality rates seen in our previous ex-
periments [9]. Also, the genotyping of the offspring is 
overly elaborate. Overall, there are still problems with the 
large-scale application of Fah−/−Rag2−/−Il2rg−/− mice. 
Azuma et al. [7] reported that human hepatocytes could 
be engrafted into Fah−/−Nod/Scid mice without any signifi-
cant proliferation, which hinted at the fact that Fah−/−Nod/ 
Scid mice may be a possible model for humanized mice. In 
the present study, we combined the advantages of liver re-
population seen in Fah−/− mice with the ease of xenotrans-
plantation seen in Nod/Scid mice to produce Fah−/−Nod/Scid 
mice by a gradual process of cross-breeding. Analysis of 
immune cells showed that the Fah−/−Nod/Scid mice lacked T 
cells, B cells and NK cells, signifying complete immune 
deficiency. The extent of this immunodeficiency was the same 
as that seen in Fah−/−Rag2−/−Il2rg−/− mice. The Fah−/−Nod/ 
Scid homozygous mice also grew healthily and reproduced 
normally. These advantages ensured a large number of re-
cipient mice for use as a chimeric liver model.  
To promote engraftment and proliferation of the trans-
planted human hepatocytes, pretreatment of the recipient 
mice is required. For example, an adenoviral vector carrying 
uPA is required for liver xeno-repopulation in 
Fah−/−Rag2−/−Il2rg−/− mice. This induces liver damage and 
promotes the proliferation of transplanted hepatocytes [7]. 
Our previous study established a simple method of inducing 
liver injury in Fah−/−Nod/Scid mice without significantly 
increasing mortality [9]. Seven days before transplantation, 
the NTBC in the drinking water of Fah−/−Nod/Scid was re-
duced to 4.0 mg L−1 (from 7.5 μg mL−1) for 3 d, and further 
reduced to 2.0 mg L−1 for 2 d. NTBC was then withdrawn  
2 d before cell transplantation. This treatment induced liver 
injury in Fah−/−-Nod/Scid mice before transplantation and 
promoted engraftment and proliferation of the transplanted 
human hepatocytes. Without this treatment (and, instead, 
abruptly removing NTBC after cell transplantation) single 
human hepatocytes only occasionally engrafted into the 
livers of Fah−/−Nod/Scid mice (data not shown).  
Gradual removal of NTBC prior to transplantation in-
duced the engraftment and proliferation of human hepato-
cytes, but the extent of liver xeno-repopulation was still 
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very low. The use of FK506 played an important role by 
improving the efficiency of liver xeno-repopulation in 
Fah−/−Nod/Scid mice. In addition to immunosuppression, 
FK506 modulates liver responses by increasing the expres-
sion of local mitogens, such as insulin-like growth factor-I, 
and insulin receptors while, at the same time, decreasing the 
production of inhibitory cytokines such as interleukin 2, to 
promote liver regeneration [18–20]. FK506 reduces macro-
phage recruitment and attenuates leukocyte accumulation, 
neutrophil infiltration and the activation of resident im-
munocompetent hepatic NK cells [21,22]. In the present 
study, Fah−/−Nod/Scid mice showed significantly enhanced 
levels of liver repopulation after treatment with FK506. Fah 
immunoassays showed that the level of engrafted Fah-posi-      
tive hepatocytes reached 33.6%. The function of expanded 
human hepatocytes was confirmed using weight curve 
analysis, the expression of characteristic proteins and by 
biochemical analysis of liver function. The results showed 
that the repopulated hepatocytes displayed the normal func-
tions of liver cells. These results show, for the first time, 
that Fah−/−Nod/Scid mice are an ideal humanized liver 
model with many applications. Our new method also sim-
plifies the protocols for generating Fah−/− mice for use as a 
humanized liver model. 
In practice, we could have chosen chimeric mice with 
complete liver xeno-repopulation according to the weight 
curves and Fah/albumin staining after partial hepatectomy. 
Mice showing >20% chimerism could then be selected for 
further study. Studies show that human hepatocytes can 
participate in the composition of the liver plate in immunode-
ficient Fah−/− mice, and are functional for a lifetime [7–9]. In 
our previous study, chimeric mice were inoculated with 
HBV virus. The virus titer increased from 103 IU mL−1 at 
eight weeks to 106 IU mL−1 at 14 weeks, confirming that the 
human hepatocytes proliferated in these mice and had nor-
mal function [9]. 
Azuma et al. [7] reported that liver xeno-repopulation in 
Fah−/−Rag2−/−Il2rg−/− mice reached up to 90%. In our pre-
vious study, human hepatocytes achieved up to 67.2% re-
population in Fah−/−Rag2−/− mice after pharmacological 
immunosuppression [9]. Tateno et al. [15] reported that 
chimeric mice died of renal atrophy and necrosis when the 
level of liver repopulation reached more than 50% because 
complement produced by the human hepatocytes caused 
damage to the uPA/SCID mouse kidneys via deposition of 
hC3 (human C3) and hMAC (human membrane attack 
complex) in the renal basilar membrane. This problem was 
solved by inhibiting the complement reaction using the pro-
teinase inhibitor, nafamostat mesilate (Futhan). After Futhan 
treatment, liver repopulation by human hepatocytes reached 
more than 90% and the chimeric mice were healthy. Bissig et 
al. [8] used Futhan pretreatment along with intravenous in-
jection of liposomes containing clodronate prior to human 
hepatocyte transplantation. The latter inhibited the function of 
the Kupffer cells in the liver and further reduced the immune 
or other factors which could affect repopulation by human 
hepatocytes and increase the levels of liver repopulation. Ac-
cording to the analysis of immune cells, the extent of immu-
nodeficiency in the Fah−/−Nod/Scid mice was equal to that in 
Fah−/−Rag2−/−Il2rg−/− mice. However, the level of liver re-
population by human hepatocytes in the Fah−/−Nod/Scid mice 
was lower than that in Fah−/−Rag2−/−Il2rg−/− mice. This might 
be related to differences in the complement response and 
Kupffer cell function between the two strains of mice. Fu-
ture studies will involve the analysis and comparison of 
these differences, leading to the optimization of the experi-
ment protocols to improve the level of liver repopulation in 
Fah−/−Nod/Scid mice. 
Humanized liver mice are an excellent model for study-
ing liver cell biology and for basic and clinical research into 
liver disease. They can be used to study the mechanisms 
underlying liver regeneration after injury and as a platform 
for evaluating drug metabolism. Humanized mice overcome 
the shortcomings of cultured cells in vitro, such as poor 
stability, short life span, and the lack of an in vivo environ-
ment. They can also be used as a new model for the preven-
tion and cure of viral hepatitis. Humanized liver mice could 
mimic the biological behavior of the human body after in-
fection by hepatotropic viruses, such as HBV and HCV. 
They are already used as model systems to study the infec-
tion and pathogenesis of hepatitis viruses, antiviral therapy, 
and vaccine efficacy. Finally, they could be used as a re-
search model for other hepatotropic pathogens, such as ma-
laria. Therefore, this model is an important innovation with 
many useful applications.  
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